Related Experiment Video
Updated: May 8, 2026

Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Formulation development and stabililty testing of extemporaneous suspension prepared from dapsone tablets
Nitin Kaila1, Mohamed El-Ries, A Riga
1Industrial Pharmacy Division, College of Pharmacy, Pharmacy Practice Department, The University of Toledo, Toledo, Ohio.
Abstract:
The qualification and quantification of dapsone in suspension were developed and shown to be stability indicating by means of a reverse-phase high-performance liquid chromatographic method. The real solubility of dapsone in water was calculated to be 0.208mg/mL at 25 deg C. The enthalpy of solution and the entropy of solution were calculated to be -175.6 J/g and -43605.7 J/K/M, respectively. An extemporaneous suspension was formulated from commercially available dapsone rablets, and the chemical stability of dapsone in the suspension was determined by means of accelerated stability testing. The 91-day analytical stabilty testing study was conducted at 4, 30, 50, 60, and 70 deg C. The energy of activation for the suspension was determined to be -23288.35 J/K/M. The zero-order rate of degradation for dapsone (k0,25) in suspension at 25 deg C was found to be 0.040845 day -1. The first-order rate of degradation for dapsone in solution was found to be 0.196370 (mg/mL)(day-1). The shelf life for the suspension was calulated to be 31.67 days at 25 deg C and 230.76 days under refrigeration at 4 deg C.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
In Vitro Drug Dissolution: Compendial Testing Models I
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
In Vitro Drug Dissolution: Compendial Testing Models II
